Two people start the same peptide therapy on the same day, follow the same protocol, and six months later one has lost a significant amount of weight while the other has barely moved the scale. This gap in response is well documented in obesity research, and it frustrates both clinicians and patients. A currently recruiting observational trial is trying to find out whether the answer to that variability is partly written in a person's DNA.
The trial, listed on ClinicalTrials.gov as NCT07653412, is focused on glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic polypeptide plus GLP-1 (GIP/GLP-1) receptor agonists. These peptide-based therapies work by mimicking naturally occurring gut hormones that regulate appetite, blood sugar, and energy balance. The trial does not test a new drug. Instead, it asks a prior question: before someone even starts one of these therapies, can a genetic score tell researchers how well that person is likely to respond?
That question sits at the heart of what scientists call precision medicine, the idea that matching a treatment to a person's biology leads to better outcomes than applying the same treatment to everyone and hoping for the best.
Why obesity genetics matter here
The trial record notes that genetic factors account for somewhere between 40 and 75 percent of a person's susceptibility to obesity. That range comes from decades of twin and family studies. More recently, large genome-wide association studies have mapped out hundreds of specific locations in the human genome where common variations are linked to body mass index, appetite signaling, energy use, and metabolic function.
No single variant flips a switch and causes obesity. Each one contributes a small nudge in one direction or another. Researchers have developed a tool called a Genetic Risk Score, or GRS, to add those nudges together into a single number. A high GRS means a person carries many of the variants associated with increased obesity risk. A low GRS means fewer of those variants are present.
GRS tools are already used in cardiovascular and diabetes research to stratify patients. Their use in predicting response to obesity pharmacotherapy, the trial record states explicitly, remains largely unexplored. That gap is exactly what this study is designed to fill.
How the trial is designed
This is a prospective observational cohort study, meaning researchers are not randomly assigning people to different treatments. Instead, they are enrolling adults who are already starting one of the two peptide therapies through their regular care and then following those participants over time.
At the starting point, researchers collect a comprehensive picture of each participant: demographic details, clinical history, body measurements, blood work, and a genetic sample. From that genetic sample, approximately 18 specific single nucleotide polymorphisms (SNPs) will be analyzed. SNPs are single-letter differences in the DNA sequence at a particular location. The 18 SNPs selected for this trial are all drawn from genes involved in appetite regulation, energy balance, and glucose metabolism.
An additive GRS is then calculated by counting the total number of risk alleles a participant carries across all 18 variants. Participants are followed for six months, with the primary outcome being the percentage of body weight lost by the end of that period.
After that six-month mark, participants are classified by how much weight they lost, and statistical models are used to test whether the GRS categories or individual SNPs predicted who ended up in which response group. The researchers also plan to combine genetic data with standard clinical variables to see whether a mixed genetic-clinical model outperforms either approach alone.
The peptides at the center of the trial
GLP-1 receptor agonists are peptides that mimic glucagon-like peptide-1, a hormone released by the gut after eating. GLP-1 slows stomach emptying, stimulates insulin release in a glucose-dependent way, and signals the brain to reduce appetite. These effects combine to reduce overall caloric intake and improve blood sugar control.
The dual GIP/GLP-1 receptor agonist used in this trial adds a second mechanism. GIP, or glucose-dependent insulinotropic polypeptide, is another gut hormone involved in energy storage and insulin sensitivity. Activating both receptors at once appears to produce greater weight reduction in many people compared with GLP-1 activation alone, though, as this trial is investigating, not everyone responds equally.
The trial is not evaluating whether these peptides work in a general sense. That question has already been answered by earlier research. The trial is asking why the size of the response differs so much from one person to the next, and whether genetic profiling can make that variability predictable before therapy even begins.
Statistical methods and what they are measuring
The analysis plan described in the trial record includes multivariable regression, a method that lets researchers test the relationship between GRS and weight loss while accounting for other variables that could confound the result, such as age, baseline body mass index, or metabolic health markers.
The trial also plans receiver operating characteristic curve analysis, a standard way to evaluate how well a predictive test separates people into two groups. In this context, the test is the GRS and the groups are responders versus non-responders. A model that performs no better than chance produces a curve that hugs the diagonal. A model with genuine predictive power curves away from it. Publishing those curves will let the research community judge whether genetic scoring has real clinical promise in this context.
Because this is an observational study rather than a randomized controlled trial, the design does not establish that genetics cause differences in response. It tests whether genetic markers are associated with those differences, which is an important distinction. Causality would require further experimental work.
What precision medicine could look like
The trial record articulates a clear motivation beyond academic curiosity. The current approach to obesity pharmacotherapy, it states, relies heavily on trial and error. A person starts one peptide therapy, waits months to see if it works, and if the response is disappointing, switches to another. That process is slow, expensive, and can be discouraging for patients.
If a GRS could reliably predict response before therapy starts, clinicians could use that information to guide the initial choice. Someone with a genetic profile associated with stronger GLP-1 pathway response might start on a GLP-1 agonist with more confidence. Someone whose profile suggests limited response through that pathway might be directed toward a dual-agonist approach or a different class of therapy entirely.
The trial record frames this as potentially contributing to individualized therapeutic selection. That framing is appropriately cautious. A single six-month cohort study will not be enough to change clinical practice on its own, but it would provide early evidence that genetic risk scoring deserves further investigation in larger and more diverse populations.
Limitations and what comes next
Observational studies have inherent limits. Participants are not randomly assigned, so differences between people who end up on one therapy versus another could introduce confounding that the statistical models only partially correct. The six-month follow-up window captures short-term response but says nothing about whether genetic predictors hold up over longer periods.
The selection of 18 SNPs is a practical compromise. Genome-wide studies have identified far more variants linked to obesity-related traits, but analyzing all of them in an observational cohort would require a much larger sample to have adequate statistical power. Focusing on 18 biologically plausible candidates is a reasonable starting point, though it means the model may miss important variation explained by other parts of the genome.
The trial is still recruiting as of its listed date, which means results are not yet available. For researchers following the precision medicine space, this study represents an early and methodologically clear attempt to connect genetic architecture to peptide therapy response. The results, when published, will either support broader investment in genetic screening before obesity pharmacotherapy or redirect the field toward other predictive approaches.
